Mirador unveils part of pipeline with drug from Kira to rival Tavneos

Mirador Therapeutics CEO Mark McKenna July 16, 2026 05:47 PM EDT StartupsDeals Mi­rador un­veils a piece of pipeline with drug from Ki­ra to ri­val trou­bled Tavneos Kyle LaHucik Biotech Correspondent Mi­rador Ther­a­peu­tics, the se­cre­tive im­mune dis­ease biotech with more than $650 mil­lion in VC fund­ing, is fi­nal­ly re­veal­ing a piece of its pipeline. The San … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER